InflaRx Appoints KPMG as New Auditor Following Shareholder Approval.

viernes, 27 de junio de 2025, 9:08 pm ET1 min de lectura
IFRX--

InflaRx has appointed KPMG as its new auditor following shareholder approval. The decision was made after EY, the previous auditor, was transitioned out. InflaRx is a biotechnology company developing anti-inflammatory therapeutics. The company's financial performance has been weak, with negative profitability and cash flow issues. Analyst ratings and valuation metrics also highlight concerns.

InflaRx Appoints KPMG as New Auditor Following Shareholder Approval.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios